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Modern life sciences with their highly sensitive omics data
face several challenges regarding data storage and sharing
[1, 2]. On the one hand data must be protected to preserve
the privacy of those individuals who contributed their data
to research. On the other hand, omics data’s true value is
only to be realized if shared with as many researchers as
possible. In an ideal world, patients can flexibly control
access to their personal data on a case-by-case basis [3].
However, granting and revoking access to data is a slow and
tedious process within the current life sciences research
paradigm, where most data is either stored on central
controlled-access data repositories or kept locally within the
respective research groups [3].
Distributed Ledger Technology (DLT; e.g., Blockchain)
recently emerged as a means to enable immutable transac-
tions between untrustworthy parties, which are kept in a
consistent state through automated, algorithm-based con-
sensus building mechanisms, thus eliminating the need for
third-party trust enforcement and giving way for patients’
direct control over the flow of their personal data [3, 4].
Furthermore, as a distributed database, DLT provides
enhanced data availability and integrity compared with
centralized data repositories [4, 5]. However, DLT is a
novel technology and although it has attracted tremendous
attention from practitioners and researchers, the genomics
community only recently started to realize DLT’s potential
for the field [3, 6]. Overall, we still lack a profound
understanding of the benefits that DLT’s application in
genomics may yield as well as associated challenges, which
is why we want to draw fellow researchers’ attention to
some of the most important opportunities and most pressing
challenges for DLT in genomics. We think that DLT’s
application in genomics can especially bring forth the fol-
lowing opportunities.
(1) Providing patients with flexible and direct access over
the flow of their personal (genome) data, thus
stimulating greater willingness to contribute data to
research.
(2) Increased security for genome data storage through
decentralization and elimination of single points of
failure.
(3) Although initiatives like ELIXIR already seek to
facilitate data sharing in the life sciences, DLT’s
inherent characteristics can strengthen such efforts,
facilitating further democratization of (genome) data
access and the breaking up of extant data silos.
At the same time, we see the following main challenges
for DLT’s meaningful application in genomics:
(1) DLT was not designed to handle omics-sized
data sets.
(2) Diverse and uncertain regulatory environments
around DLT (e.g., putting genomic data on a
distributed ledger is a difficult-to-reverse decision,
which might require very high efforts and thus
contradict the right to be forgotten as stipulated by
the European Union’s General Data Protection
Regulation (GDPR)).
(3) Applications of DLT in genomics currently mainly
revolve around young businesses like Nebula Geno-
mics, EncrypGen, or Genecoin, to name but a few,
that aim at building marketplaces where consumers
can trade their private genome data for tokens. While
such monetization of genome data sharing will likely
attract an increasing number of people to share their
genome data, many will do so predominantly for
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monetary reasons without being fully aware of the
implications, thus creating new ethical challenges.
European researchers have traditionally been leading voi-
ces about the dangers and ethical implications of large-scale
access to and use of genome data [7]. Genomics is highly
regulated within Europe and genome tests for medical or
predictive purposes must be carried out by trained profes-
sionals in most European Union member states [8]. Conse-
quently, compared with the US and other regions of the
world, the direct-to-consumer genetic testing market in Eur-
ope, for example, is much smaller and there are fewer
incentives for building DLT-based genome data markets
where European consumers can trade their private genome
data. However, while the past has taught us that one can
easily fall behind in the fast-paced technology sector, we also
firmly believe in the European way of cautiously balancing
the benefits of large-scale genome data access with the per-
sonal and societal risks that arise with such. Building on the
spirit that has spawned initiatives for the open and large-scale
sharing of genome data [9], we therefore call for more
attention to the surging phenomenon of DLT in genomics
from European researchers and institutions. In particular, we
see the following avenues for European researchers and
institutions to contribute to the proliferation of DLT in
genomics with a European character. First, we should focus
on applying DLT as a tool for researchers that allows indi-
viduals to contribute to genomic research while putting less
emphasis on establishing yet another genome data market for
consumers. Although researchers have already begun to do so
(e.g., Lee et al. [10], Ozercan et al. [3], or the iDASH Privacy
and Security Workshops 2018 and 2019), more efforts in this
direction are necessary. Second, we should investigate means
for how DLT can manage omics-sized data while still pro-
viding strong information security and privacy in accordance
with contemporary European legislation like the GDPR.
Third, create a European distributed ledger for genomics (e.g.,
a European genomics Blockchain), which serves as a light-
house project, helps breaking up extant data silos, and
encourages collaborations among researchers from different
institutes and countries across and beyond Europe. Thereby,
extant initiatives like ELIXIR could be a fruitful starting
ground for setting up such a European distributed ledger for
genomics.
Although only time can tell whether DLT can live up to
the current hype and meet everyone’s expectations, we
believe that in pursuing these avenues, we will be able to
realize DLT’s full potential for genomics, beyond mere
genome data markets.
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